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Abstract
Introduction: Chondrosarcoma is well-known to be primarily resistant to conventional radiation and
chemotherapy.
Case presentation: We present the case of a 32-year-old Caucasian man with clear cell chondrosarcoma who
presented with symptomatic recurrence in his pelvis and metastases to his skull and lungs. Our patient underwent
systemic therapy with sunitinib and then consolidation with proton beam radiation to his symptomatic site. He
achieved complete symptomatic relief with a significantly improved performance status and had an almost
complete and durable metabolic response on fluorine-18-fluorodeoxyglucose positron emission tomography.
Conclusions: Our findings have important clinical implications and suggest novel clinical trials for this difficult to
treat disease.
Introduction
Chondrosarcomas are malignant tumors that arise from
cartilaginous tissue and comprise four major subtypes:
mesenchymal, clear cell, conventional and dedifferen-
tiated [1,2]. In about half of cases, tumors develop from
large bones of the lower extremities and in one-fifth,
disease is metastatic upon presentation. Except for the
mesenchymal subtype, chondrosarcomas are primarily
resistant to conventional radiation and chemotherapy
[1,3,4]. Surgical resection remains the primary treatment
option [5]. For patients with unresectable disease, the
prognosis is dismal and symptoms can be debilitating
due to sites of disease involvement.
Recent advances in the molecular understanding of
sarcomas and the development of targeted therapy for
sarcoma treatment have led to interest in the possibility
of testing targeted agents in chondrosarcomas [6]. Gene
expression profiling has identified high levels of tyrosine
kinase and receptor tyrosine kinase expression in a
number of sarcoma types, indicating that sarcomas may
potentially be candidates for therapy with tyrosine
kinase inhibitors [7-14]. In chondrosarcoma, the platelet
derived growth factor receptor (PDGFR) tyrosine kinase
pathway has also been shown to be activated, as evi-
denced by the overexpression of both PDGFR-a and -b
and increased PDGFR signaling activity [15,16]. Due to
its inhibition of the PDGFR tyrosine kinase pathway, we
hypothesize that sunitinib would have beneficial activity
in chondrosarcoma.
Case presentation
We present the case of a 32-year-old Caucasian man
who initially presented five years previously with right
hip pain and was found at that time to have a large
multilobulated mass arising from his right ilium and
extending to his right sacrum with involvement of his
gluteal musculature (Figure 1A). A biopsy showed a
grade 1 chondrosarcoma. Subsequently, a right hemipel-
vectomy was performed, and the diagnosis of grade 1
chondrosarcoma arising from a pre-existing osteochon-
droma was confirmed (Figure 2A). Additionally, a minor
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at the origin of the osteochondroma within the medul-
lary cavity of the underlying ileum (Figure 2B). Recur-
rence in the sacral stump and an area adjacent to his
paraspinous muscles was noted two years later after our
patient experienced a fall. He underwent proton beam
radiotherapy and resection, complicated by a postsurgi-
cal abscess.
Approximately two-and-a-half years later, our patient
presented with significant pain in his right pelvis, diffi-
culty in ambulating and a decreased performance status
due to pain. A bone scan showed uptake in his left tem-
poral bone and an excisional biopsy confirmed recur-
rence of the clear cell chondrosarcoma (Figure 2C). A
positron emission tomography/computed tomography
(PET/CT) scan showed uptake to an standardized
uptake value (SUV) maximum of 9.0 in the right sacral
lesion with two other areas of uptake in his pelvis
(Figure 1B). Two non-hypermetabolic pulmonary
nodules were also noted. Stereotactic radiosurgery was
applied to the temporal bone lesion. Our patient was
started on sunitinib 37.5 mg daily, which was initially
tolerated well, with only mild fatigue. His pain greatly
improved. A PET/CT scan obtained two months after
the initiation of sunitinib showed improvement in the
fluorine-18-fluorodeoxyglucose (FDG)-avidity of the
lesions, with a right sacral lesion showing an SUV of 6.8
(Figure 1B). He continued to take sunitinib at the same
dose and was referred for proton beam radiation to his
right pelvis. He received twenty fractions of radiation
concurrent with sunitinib 37.5 mg daily and experienced
some diarrhea and worsening of an acneiform rash, but
our patient wished to continue on the same dose given
his excellent response with regards to the pain. A total
of six months after initiating sunitinib, our patient con-
tinued to show improvement on imaging, with a PET/
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Figure 1 Representative scans done upon diagnosis and during the course of sunitinib treatment. (A) Diagnostic computed tomography
showing the multilobulated chondrosarcoma mass arising from his right pelvis. (B) Superimposed fluorine-18- fluorodeoxyglucose-positron
emission tomography and computed tomography scans showing the pelvis mass (white arrow) immediately prior to sunitinib, two months after
initiation of sunitinib alone and two months after combined sunitinib and proton beam radiation. Intensity of fluorine-18-fluorodeoxyglucose
uptake: red, high; yellow, intermediate; blue, low.
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Figure 2 Hematoxylin and eosin staining of sections from our patient’s pelvic tumor mass and skull metastasis. (A) Low-power
photomicrograph demonstrating the low-grade chondrosarcoma (black arrows) arising in the stalk of a pre-existing osteochondroma (white
arrows). (B) Focally within the stalk of the osteochondroma, the tumor had features of clear cell chondrosarcoma. (C) The skull metastasis
consisted entirely of the clear cell chondrosarcoma component.
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nodules and improvement in the right sacral lesion with
an SUV of 3.4 (Figure 1B). He did require a reduction
in the dose 25 mg daily, however, due to the worsening
acneiform rash and diarrhea.
Discussion
Sunitinib is a multitargeted receptor tyrosine kinase
inhibitor that exhibits inhibitory activity against multiple
targets including c-KIT, vascular endothelial growth fac-
tor receptors (VEGFR; VEGFR1, VEGFR2 and VEGFR3),
PDGFR-a and -b,f m s - l i k et y r o s i n ek i n a s er e c e p t o r - 3 ,
colony stimulating factor 1 receptor, and RET [17,18].
Inhibition of these receptor tyrosine kinases blocks the
transduction of signals important for tumor growth, sur-
vival and angiogenesis. Phase II and III clinical trials
with sunitinib have shown clinical benefit, with signifi-
cantly improved progression-free and overall survival in
patients with imatinib-resistant gastrointestinal stromal
tumors (GIST) and advanced renal cell carcinoma
[19,20]. A phase II study showed that continuous use of
sunitinib in advanced or metastatic non-GIST sarcomas
produced a noteworthy metabolic response in many
patients [11].
In a murine model, sunitinib was shown to be syner-
gistic with radiation in increasing apoptosis in endothe-
lial cells, enhancing destruction of the tumor
vasculature and increasing time to tumor growth [21].
While tumors regrew rapidly after the discontinuation
of sunitinib in this study, it was also shown that restart-
ing sunitinib therapy resulted in further growth delays,
suggesting that patients can benefit from maintenance
therapy with sunitinib after the completion of radiation.
Kao et al. published results of a phase I study employ-
ing sunitinib concurrent with stereotactic radiation for
patients with oligometastatic disease [22]. In the study,
21 patients with one to five sites of metastatic disease of
any solid tumor type were treated with sunitinib, start-
ing at 25 mg daily, with radiation to 40Gy in 10 frac-
tions. The doses of both the radiation and the sunitinib
were increased as tolerated, leading to a dosing recom-
mendation for sunitinib with radiation at 37.5 mg daily.
Sunitinib in conjunction with radiation yielded a com-
p l e t er e s p o n s ei n4 2 %o ft h el e s i o n s ,w i t hap a r t i a l
response in 17% and stable disease in 28%. At the last
follow-up, 38% of these patients were without evidence
of disease.
Conclusions
Our study is the first to show that sunitinib has benefi-
cial activity in chondrosarcoma and may be safely com-
bined with proton beam radiation therapy. Randomized
phase II or III clinical trials are needed to assess the
role of sunitinib in this disease and as a radiosensitizer.
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